Vaccine Therapy and Sargramostim in Treating Patients With Non-small Cell Lung Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically proven stage IB-IV non-small cell lung cancer
• •* Non-squamous cell histology only
• •* Must have undergone curative surgery within the past 6 months and must be free of recurrence
• •* Tumor must demonstrate a specific K-ras mutation at codon 12 for which a vaccine preparation is available
• •PATIENT CHARACTERISTICS:
• •Age:
• •Over 17
• •Performance status:
• •Karnofsky 70-100%
• •Life expectancy:
• •Not specified
• •Hematopoietic:
• •WBC at least 3,000/mm\^3
• •Platelet count at least 100,000/mm\^3
• •Hepatic:
• •Not specified
• •Renal:
• •Not specified
• •Cardiovascular:
• •No New York Heart Association class III or IV heart disease
• •Other:
• •Not pregnant or nursing
• •Fertile patients must use effective contraception
• •No concurrent medical condition that would preclude compliance or immunologic response to study treatment
• •No other serious concurrent medical condition
• •No other malignancy within the past 5 years except nonmelanomatous skin cancer or carcinoma in situ of the uterine cervix
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •Not specified
• •Chemotherapy:
• •At least 3 weeks since prior postoperative chemotherapy and recovered
• •Endocrine therapy:
• •No concurrent systemic steroids
• •Concurrent inhaled steroids allowed
• •Radiotherapy:
• •No prior radiotherapy to spleen
• •At least 3 weeks since prior postoperative radiotherapy and recovered
• •Surgery:
• •See Disease Characteristics
• •No prior splenectomy
• •Other:
• •No concurrent immunosuppressive drugs or antiinflammatory drugs